Detailed information for compound 427126

Basic information

Technical information
  • TDR Targets ID: 427126
  • Name: 3-chloro-N-[4-chloro-2-[(4-chlorophenyl)carba moyl]phenyl]-4-[(4-methylpiperazin-1-yl)methy l]thiophene-2-carboxamide
  • MW: 537.889 | Formula: C24H23Cl3N4O2S
  • H donors: 2 H acceptors: 2 LogP: 5.69 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 2
  • SMILES: CN1CCN(CC1)Cc1csc(c1Cl)C(=O)Nc1ccc(cc1C(=O)Nc1ccc(cc1)Cl)Cl
  • InChi: 1S/C24H23Cl3N4O2S/c1-30-8-10-31(11-9-30)13-15-14-34-22(21(15)27)24(33)29-20-7-4-17(26)12-19(20)23(32)28-18-5-2-16(25)3-6-18/h2-7,12,14H,8-11,13H2,1H3,(H,28,32)(H,29,33)
  • InChiKey: FIZKTFMGWNHPMZ-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 3-chloro-N-[4-chloro-2-[(4-chloroanilino)-oxomethyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide
  • 3-chloro-N-[4-chloro-2-[(4-chlorophenyl)carbamoyl]phenyl]-4-[(4-methylpiperazino)methyl]thiophene-2-carboxamide
  • 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]-oxomethyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide
  • 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL)AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE
  • XLC

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens coagulation factor X Starlite/ChEMBL References
Homo sapiens coagulation factor II (thrombin) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium tuberculosis Probable aldehyde dehydrogenase 0.0059 0.2631 0.5
Loa Loa (eye worm) pigment dispersing factor receptor c 0.0048 0.1895 1
Mycobacterium ulcerans aldehyde dehydrogenase 0.0059 0.2631 0.5
Schistosoma mansoni aldehyde dehydrogenase 0.0059 0.2631 0.2631
Toxoplasma gondii aldehyde dehydrogenase 0.0059 0.2631 0.3997
Leishmania major aldehyde dehydrogenase, mitochondrial precursor 0.0059 0.2631 1
Plasmodium falciparum MO15-related protein kinase 0.0124 0.7152 1
Toxoplasma gondii cell-cycle-associated protein kinase, putative 0.0116 0.6583 1
Mycobacterium ulcerans aldehyde dehydrogenase 0.0059 0.2631 0.5
Brugia malayi Calcitonin receptor-like protein seb-1 0.0048 0.1895 1
Echinococcus multilocularis geminin 0.0165 1 1
Schistosoma mansoni hypothetical protein 0.0033 0.0826 0.0826
Loa Loa (eye worm) hypothetical protein 0.0033 0.0826 0.4359
Schistosoma mansoni hypothetical protein 0.0165 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0021 0 0.5
Schistosoma mansoni aldehyde dehydrogenase 0.0059 0.2631 0.2631
Schistosoma mansoni hypothetical protein 0.0165 1 1
Brugia malayi Corticotropin releasing factor receptor 2 precursor, putative 0.0048 0.1895 1
Brugia malayi latrophilin 2 splice variant baaae 0.0033 0.0826 0.4359
Mycobacterium ulcerans aldehyde dehydrogenase 0.0059 0.2631 0.5
Echinococcus multilocularis aldehyde dehydrogenase, mitochondrial 0.0059 0.2631 0.2631
Onchocerca volvulus 0.0021 0 0.5
Echinococcus granulosus aldehyde dehydrogenase mitochondrial 0.0059 0.2631 0.2631
Loa Loa (eye worm) hypothetical protein 0.0048 0.1895 1
Plasmodium vivax cyclin dependent kinase 7 (cdk7), putative 0.0124 0.7152 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 12 uM Anticoagulant potency in human plasma assessed as concentration for doubling of prothrombin time ChEMBL. 17536795
CL (ADMET) = 0.3 L/hr.Kg Clearance in beagle dog at 1 mg/kg, iv ChEMBL. 17227710
Cmax (ADMET) = 6.3 uM Plasma concentration in beagle dog at 10 mg/kg, po ChEMBL. 17227710
Cp (functional) = 12 uM Anticoagulant activity in human plasma assessed as concentration required to double prothrombin time ChEMBL. 17227710
F (ADMET) = 41 % Bioavailability in beagle dog at 10 mg/kg, po ChEMBL. 17227710
Ki (binding) = 0.76 nM Inhibition of human F10a ChEMBL. 17536795
Ki (binding) = 1 nM Binding affinity to human factor 10a after 10 mins ChEMBL. 17227710
Ki (binding) = 840 nM Inhibition of human F2a ChEMBL. 17536795
Ki (binding) = 910 nM Binding affinity to human thrombin after 10 mins ChEMBL. 17227710
Ki app (binding) = 0.76 nM Inhibition of human F10a ChEMBL. 17536795
Ki app (binding) = 1 nM Binding affinity to human factor 10a after 10 mins ChEMBL. 17227710
Ki app (binding) = 840 nM Inhibition of human F2a ChEMBL. 17536795
Ki app (binding) = 910 nM Binding affinity to human thrombin after 10 mins ChEMBL. 17227710
Ki app (binding) > 5000 nM Binding affinity to bovine trypsin after 10 mins ChEMBL. 17227710
Ki/Km (binding) > 5000 nM Inhibition of bovine trypsin ChEMBL. 17536795
Log D = 2.96 Distribution coefficient, log D of the compound at pH 7.4 ChEMBL. 17536795
t1/2 (ADMET) = 2 hr Half life in beagle dog at 1 mg/kg, iv ChEMBL. 17227710
Vdss (ADMET) = 0.7 L/Kg Volume of distribution at steady state in beagle dog at 1 mg/kg, iv ChEMBL. 17227710

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.